Comparison Between Direct Oral Anticoagulation (DOAC) Interruption and DOAC Continuation in Patients Undergoing Elective Invasive Coronary Angiography or Percutaneous Coronary Intervention

ConditionsAtrial Fibrillation Coronary Artery Disease Anticoagulants

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18+

SponsorZuyderland Medisch Centrum

About this trial

A prospective, multicenter, 1:1 randomized, investigator initiated study. Goal of this study is to examine the safety of uninterrupted periprocedural DOAC use.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients aged >18 years using DOAC and undergoing elective ICA or PCI.

Provided signed informed consent

Disqualifiers

Patients initially presenting with Acute Coronary Syndrome (STEMI, NSTEMI, UA)

Patients <18 years old

Calculated creatinine clearance <30 mL/min

Patients simultaneously participating in another clinical trial

Trial design

Design model

Parallel

Treatments tested in this trial

Uninterrupted DOAC use
Other intervention
Continuing DOAC use in advance of elective ICA or PCI.
Interrupted DOAC use
Other intervention
Usual care, interruption of DOAC prior to procedure.

Treatment groups

1,270 Participants

are divided into 2 treatment groups

Group A: Interrupted DOAC use (group 1)Active comparator 1 intervention

Group B: Uninterrupted DOAC use (group 2)Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

Major Bleeding

Non-CABG related in-hospital bleeding (BARC 2, 3 or 5)

Time frame

30 days

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Zuyderland Medisch Centrum

Lead sponsor

Source ClinicalTrials.gov

Apply now